Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
GSIW - Garden Stage Limited Ordinary Shares - Stock Price Chart
TickerGSIW [NASD]
CompanyGarden Stage Limited Ordinary Shares
CountryHong Kong
IndustryAsset Management
Market Cap-EPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume-52W Range- - -
Garden Stage is a Hong Kong-based financial services provider principally engaged in the provision of (i) placing and underwriting services; (ii) securities dealing and brokerage services; and (iii) asset management services. Our business is carried out through our wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong. I Win Securities is the Stock Exchange Participant and holds one Stock Exchange Trading Right. In addition, I Win Securities is a participant of the HKSCC.
NEXI - Neximmune Inc - Stock Price Chart
TickerNEXI [NASD]
CompanyNeximmune Inc
CountryUSA
IndustryBiotechnology
Market Cap6.41MEPS (ttm)-267.72
P/E-EPS this Y63.85%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-40.76%
P/S-EPS next 5Y-
P/B0.03EPS Q/Q-1458.48%
Dividend-Sales Q/Q-
Insider Own37.79%Inst Own16.11%
Insider Trans-1.92%Inst Trans-78.11%
Short Float0.99%EarningsAug 10/a
Analyst Recom1.00Target Price125.00
Avg Volume23.42K52W Range1.25 - 20.35
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roemer Alan S.DirectorNov 22Sale1.943,9927,7580Nov 22 05:18 PM
Roemer Alan S.DirectorNov 21Sale2.163,8338,2873,992Nov 22 05:18 PM
BARER SOL JDirectorMar 30Buy0.41400,000164,1202,217,814Mar 31 04:56 PM
GGE - Green Giant Inc - Stock Price Chart
TickerGGE [NASD]
CompanyGreen Giant Inc
CountryChina
IndustryReal Estate - Development
Market Cap17.01MEPS (ttm)-3.98
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S9.10EPS next 5Y-
P/B0.51EPS Q/Q-4493.79%
Dividend-Sales Q/Q-63.06%
Insider Own32.27%Inst Own0.04%
Insider Trans0.00%Inst Trans-
Short Float0.13%Earnings-
Analyst Recom-Target Price-
Avg Volume1.39M52W Range0.16 - 3.42
Green Giant, Inc. engages in real estate development, primarily in the construction and sale of residential apartments, car parks, and commercial properties. Its projects include the Mingzhu Beiyuan, Oriental Pearl Garden, and Liangzhou Road, which are located in Hanzhong City; and the Yangzhou Pearl Garden and Yangzhou Palace, which are located in Yang County. The company was founded by Xiao Jun Zhu in 1995 and is headquartered in Hanzhong, China.
PAPL - Pineapple Financial Inc - Stock Price Chart
TickerPAPL [AMEX]
CompanyPineapple Financial Inc
CountryCanada
IndustryMortgage Finance
Market Cap15.80MEPS (ttm)-0.29
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.90EPS next 5Y-
P/B9.27EPS Q/Q-20.49%
Dividend-Sales Q/Q-36.65%
Insider Own55.70%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float4.37%Earnings-
Analyst Recom-Target Price-
Avg Volume728.62K52W Range1.28 - 4.25
Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company. It provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages and consumers. The company also provide back office services, together with pre-underwriting support services. Pineapple Financial was founded by Shubha Dasgupta, Kendall Marin and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.
BETS - Bit Brother Limited - Stock Price Chart
TickerBETS [NASD]
CompanyBit Brother Limited
CountryChina
IndustryCapital Markets
Market Cap8.20MEPS (ttm)-1.24
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y77.03%
P/S2.85EPS next 5Y-
P/B0.21EPS Q/Q38.51%
Dividend-Sales Q/Q72.46%
Insider Own7.37%Inst Own0.43%
Insider Trans0.00%Inst Trans-
Short Float1.73%Earnings-
Analyst Recom-Target Price-
Avg Volume24.47M52W Range0.02 - 12.00
Bit Brother Ltd. Is a holding company, which engages in the supply and distribution of tea beverages and related products. It operates through the Tea Shop Chains, and Block Chain and Digital Asset Mining segments. The company was founded on November 28, 2011, and is headquartered in Changsha, China.
NEGG - Newegg Commerce Inc - Stock Price Chart
TickerNEGG [NASD]
CompanyNewegg Commerce Inc
CountryUSA
IndustryInternet Retail
Market Cap679.97MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y42.14%
P/S-EPS next 5Y-
P/B3.98EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own94.75%Inst Own0.40%
Insider Trans0.00%Inst Trans1.40%
Short Float9.83%Earnings-
Analyst Recom1.00Target Price3.00
Avg Volume665.65K52W Range0.52 - 3.09
Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.
ESTC - Elastic N.V - Stock Price Chart
TickerESTC [NYSE]
CompanyElastic N.V
CountryUSA
IndustrySoftware - Application
Market Cap10.85BEPS (ttm)-1.98
P/E-EPS this Y310.30%
Forward P/E73.85EPS next Y45.47%
PEG-EPS past 5Y-8.38%
P/S9.36EPS next 5Y-
P/B24.12EPS Q/Q49.57%
Dividend0.03%Sales Q/Q17.48%
Insider Own19.02%Inst Own76.34%
Insider Trans-2.36%Inst Trans1.72%
Short Float5.01%EarningsNov 30/a
Analyst Recom1.84Target Price102.61
Avg Volume1.35M52W Range46.18 - 84.04
Dec-01-23Upgrade Wells Fargo Equal Weight → Overweight $90 → $108
Elastic NV is a data analytics company, which engages in the provision of open-source search and analytics engine services. It operates through the United States, the Netherlands, United Kingdom, India, and Rest of World geographical segments. The company was founded by Shay Banon, Uri Boness, Steven Schuurman, and Simon Willnauer on February 9, 2012 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chadwick JonathanDirectorOct 02Option Exercise19.8725,000496,75032,729Oct 04 04:44 PM
Chadwick JonathanDirectorOct 02Sale81.3825,0002,034,5847,729Oct 04 04:44 PM
Herzog CarolynChief Legal OfficerSep 12Sale78.251,320103,29080,702Sep 13 04:56 PM
Moorjani JaneshCFO & COOSep 11Option Exercise13.073594,692129,502Sep 13 04:55 PM
Kulkarni AshutoshChief Executive OfficerSep 11Sale77.8314,3761,118,942317,953Sep 13 04:56 PM
CNFR - Conifer Holdings Inc - Stock Price Chart
TickerCNFR [NASD]
CompanyConifer Holdings Inc
CountryUSA
IndustryInsurance - Property & Casualty
Market Cap15.89MEPS (ttm)-0.35
P/E-EPS this Y35.25%
Forward P/E-EPS next Y91.14%
PEG-EPS past 5Y18.26%
P/S0.14EPS next 5Y15.00%
P/B1.35EPS Q/Q-61.37%
Dividend-Sales Q/Q7.03%
Insider Own72.28%Inst Own7.03%
Insider Trans0.00%Inst Trans-1.78%
Short Float0.53%EarningsNov 09/a
Analyst Recom5.00Target Price0.61
Avg Volume5.80K52W Range0.65 - 2.08
Conifer Holdings, Inc. engages in the sale of property and casualty insurance products. It operates through the following segments: Commercial Lines, Personal Lines, Underwriting, Wholesale Agency, and Corporate. The company was founded on October 27, 2009 and is headquartered in Troy, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PETCOFF JAMES GExecutive Chairman and Co-CEOMar 24Buy1.51200,000302,000680,275Mar 27 04:05 PM
PETCOFF JAMES GExecutive Chairman and Co-CEODec 30Sale1.50200,000300,0002,698,607Jan 03 05:06 PM
COYA - Coya Therapeutics Inc - Stock Price Chart
TickerCOYA [NASD]
CompanyCoya Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap68.85MEPS (ttm)-1.24
P/E-EPS this Y71.19%
Forward P/E-EPS next Y-24.20%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B6.82EPS Q/Q17.19%
Dividend-Sales Q/Q-
Insider Own18.75%Inst Own14.24%
Insider Trans0.00%Inst Trans-
Short Float0.43%EarningsNov 08/b
Analyst Recom1.00Target Price13.00
Avg Volume49.36K52W Range3.21 - 8.00
Nov-08-23 09:00AM Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results (Business Wire)
Oct-27-23 09:00AM Coya Announces Acceptance of Oral Presentation, Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimers Disease: A Phase 1 Feasibility Study, at the 18th International Conference on Alzheimers and Parkinsons Disease in Lisbon (Business Wire)
Oct-09-23 08:00AM Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimers Disease (AD) (Business Wire)
Oct-05-23 09:00AM Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire)
Oct-03-23 09:00AM Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire) -5.38%
Sep-27-23 09:00AM Coya Therapeutics to Present at the LD Micro Investor Conference (Business Wire)
Sep-22-23 09:00AM Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU) (Business Wire)
Sep-07-23 09:15AM Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases (Business Wire) +12.12%
Aug-31-23 08:00AM Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies (Business Wire)
Aug-25-23 09:00AM Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023 (Business Wire)
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
INTS - Intensity Therapeutics Inc - Stock Price Chart
TickerINTS [NASD]
CompanyIntensity Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap43.19MEPS (ttm)-0.67
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B2.71EPS Q/Q-25.39%
Dividend-Sales Q/Q-
Insider Own41.08%Inst Own2.18%
Insider Trans0.00%Inst Trans-
Short Float0.05%EarningsNov 13/b
Analyst Recom1.00Target Price12.00
Avg Volume12.93K52W Range2.01 - 6.75
Dec-01-23 08:01AM Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium (PR Newswire) +28.55%
Nov-13-23 08:01AM Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-23 07:01AM Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023 (PR Newswire)
Sep-07-23 08:01AM Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma (PR Newswire)
Sep-05-23 08:01AM Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 07:01AM Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 07:01AM Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire)
Jul-31-23 04:05PM Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire)
Jul-10-23 08:00AM Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds (PR Newswire)
Jul-05-23 04:15PM Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds (PR Newswire)
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.
1234561020